NCT06285799View on ClinicalTrials.gov

Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women

PHASE3CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

February 11, 2025

Study Completion Date

February 15, 2025

Conditions

Iron-deficiency

Interventions

DRUG

Low Dose IHAT

Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)

DRUG

High Dose IHAT

Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)

DRUG

Carob Flour

Twice daily dose of 1 placebo capsule (carob flour)

Trial Locations (1)

4006

RDC Clinical Pty Ltd, Brisbane

All Listed Sponsors

collaborator

RDC Clinical Pty Ltd

INDUSTRY

lead

Nemysis Ltd

INDUSTRY

NCT06285799 - Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women | Biotech Hunter | Biotech Hunter